MYCBP

c-Myc-binding protein · Q99417 · MYCBP on Sugi Atlas →

0 patent compounds predicted against MYCBP, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MYCBP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors PHASE1/PHASE2COMPLETED
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL PHASE2ACTIVE_NOT_RECRUITING
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis PHASE2ACTIVE_NOT_RECRUITING
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; PHASE2COMPLETED
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma PHASE2COMPLETED
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders PHASE1/PHASE2COMPLETED
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma PHASE2COMPLETED
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma PHASE2COMPLETED
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies PHASE1RECRUITING
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA PHASE1RECRUITING
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery nanWITHDRAWN
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma nanRECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases nanRECRUITING
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Establishment of a Prospective Clinical-biological Database nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MYCBP binder may also engage these)

ProteinNameSimilarity
Q2TBP7 1.000 Q2TBP7 →
Q9EQS3 1.000 Q9EQS3 →
Q5R7A8 1.000 Q5R7A8 →
Q9UJC3 0.982 Q9UJC3 →
Q6GQ73 0.979 Q6GQ73 →
Q0P4J3 0.977 Q0P4J3 →
Q6A028 0.977 Q6A028 →
Q5RA03 0.977 Q5RA03 →
Q9BR77 0.977 Q9BR77 →
Q54I57 0.977 Q54I57 →
Q8BUK6 0.977 Q8BUK6 →
Q8VD46 0.976 Q8VD46 →
A0JMY4 0.976 A0JMY4 →
Q3ZC62 0.976 Q3ZC62 →
Q6P0R8 0.975 Q6P0R8 →
Q96G28 0.975 Q96G28 →
Q7T0S7 0.975 Q7T0S7 →
Q7SYB5 0.975 Q7SYB5 →
Q2QLA4 0.974 Q2QLA4 →
Q2TAA8 0.974 Q2TAA8 →
Q0P4W3 0.974 Q0P4W3 →
Q5EAU9 0.974 Q5EAU9 →
Q6DF11 0.974 Q6DF11 →
Q6NWC9 0.974 Q6NWC9 →
Q09YH1 0.974 Q09YH1 →
Q5ZJ27 0.974 Q5ZJ27 →
Q4R7Y8 0.974 Q4R7Y8 →
Q2IA00 0.974 Q2IA00 →
Q9D8Y8 0.974 Q9D8Y8 →
Q99P25 0.974 Q99P25 →